Immune and cellular determinants of response to HMA-venetoclax regimens in acute myeloid leukemia - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Immune and Cellular Factors Shaping Response to Hypomethylating Agent–Venetoclax Therapy in Acute Myeloid Leukemia

  • By

  • Alfredo Marchetti

  • Francesca Lazzaroni

  • Matteo Claudio Da Via'

  • Marta Lionetti

  • Giulia Maggioni

  • Alessia Campagna

  • Denise Ventura

  • Giorgio A. Croci

  • Alessio Marella

  • Akihiro Maeda

  • Antonio Matera

  • Emanuele Calvi

  • Margherita Scopetti

  • Filippo Viviani

  • Nicolò Rampi

  • Davide Bonometti

  • Elena Benzoni

  • Manuela Zappa

  • Sonia Fabris

  • Marzia Barbieri

  • Stefania Pioggia

  • Claudia Leoni

  • Antony Ricchiuti

  • Matteo G. D. Porta

  • Mariarita Sciumè

  • Francesco Passamonti

  • Nicola S. Fracchiolla

  • Niccolò Bolli

  • October 13, 2026

Share

  • 1

    The retrospective cohort included 132 patients with AML treated with hypomethylating agents plus venetoclax.

  • 2

    Molecular profiling was available for 99 patients, with TET2, DNMT3A, and NPM1 among the most frequent mutations.

  • 3

    Single-cell RNA sequencing was performed in 10 patients at diagnosis and after the first treatment cycle.

  • 4

    Single-cell patients were classified as responders, early-relapse patients, or refractory patients based on response after cycle one and subsequent treatment failure.

  • 5

    The study examined genomic and immune features associated with response to hypomethylating agent–venetoclax therapy, focusing on early treatment timepoints.

Original Source(s)

Immune and cellular determinants of response to HMA-venetoclax regimens in acute myeloid leukemia

  • by Alfredo Marchetti, Francesca Lazzaroni, Matteo Claudio Da Via', Marta Lionetti, Giulia Maggioni, Alessia Campagna, Denise Ventura, Giorgio A. Croci, Alessio Marella, Akihiro Maeda, Antonio Matera, Emanuele Calvi, Margherita Scopetti, Filippo Viviani, Nicolò Rampi, Davide Bonometti, Elena Benzoni, Manuela Zappa, Sonia Fabris, Marzia Barbieri, Stefania Pioggia, Claudia Leoni, Antony Ricchiuti, Matteo G. D. Porta, Mariarita Sciumè, Francesco Passamonti, Nicola S. Fracchiolla, Niccolò Bolli

  • October 13, 2026

Related Content

Depth of Invasion as a Predictor of Contralateral Nodal Metastasis in Lateralized Oral Tongue Squamous Cell Carcinomas

2026 ASCO Breast Cancer Highlights: Triple Negative Breast Cancer

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new antibody drug conjugate treatment options in first line triple negative breast cancer.

  • October 15, 2026

  • 1 min
2026 ASCO Breast Cancer Highlights: persevERA

Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH, discuss the persevERA trial and oral SERDS in metastatic breast cancer.

  • October 15, 2026

  • 1 min